Loading company…
META FINES develops low-toxicity anticancer and palliative drugs.
Based in Seongnam, South Korea, META FINES develops low-toxicity drugs for cancer treatment and palliative care. Its ASCA101 technology targets intractable and terminal cancers, and its pipeline includes drugs for cancer cachexia. In April 2022, the company raised KRW 20 billion in Series B funding from DSC Investment, BMIKOREA, Industrial Bank of Korea, and Prodigy Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in